Evan Feinberg

Founder and Chief Executive Officer Genesis Molecular AI

Last Reviewed: September 24, 2026

Executive Summary

Evan Feinberg is the founder and Chief Executive Officer of Genesis Molecular AI, a San Francisco Bay Area company building AI for small molecule drug discovery. He started it in 2019, as Genesis Therapeutics, to develop AI and simulation research from his doctoral work in Vijay Pande’s lab at Stanford. The company’s core idea is to combine machine-learned foundation models with physics-based simulation, instead of relying on either one alone. Its GEMS platform and its Pearl structure-prediction model are the commercial result. Genesis has raised substantial venture funding and has a growing partnership with Incyte, which in May 2026 committed $80 million in upfront cash and a $40 million equity investment.

Career Highlights

• Founded Genesis in 2019 and leads it as Founder and Chief Executive Officer; SEC Form D filings from 2020 to 2023 list him as an executive officer and director.
• Developed PotentialNet, a physics-based machine learning framework for drug targets with limited data, during his PhD research at Stanford.
• Genesis’s August 2023 Form D reported $224 million sold in an equity offering, after raises of $49.5 million (2020) and $23.9 million (2022).
• Genesis launched Pearl, a foundation model for drug discovery, in October 2025.
• In May 2026 he announced an expanded collaboration with Incyte, which includes $80 million upfront, a $40 million equity purchase and at least five new targets.

Professional Journey

Feinberg studied applied physics at Yale and then took a PhD in computational biophysics at Stanford. There he worked in Vijay Pande’s lab on AI and simulation. His doctoral research produced PotentialNet, a machine learning framework built on physical principles and designed for drug targets that have little experimental data. According to the company, the work was published in journals including Science, Nature, ACS Central Science and the Journal of Medicinal Chemistry.

In 2019 he founded Genesis Therapeutics to turn that research into a drug discovery platform. Pande later sat on the company’s board, as shown in its 2023 SEC filing. Genesis filed its first Form D in December 2020, reporting $49.5 million sold, and then filed for $23.9 million in 2022. In August 2023 it filed for $224 million, the largest of the three. Feinberg is listed as an executive officer and director in every one of these filings. The company names its investors as a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity and Radical Ventures.

The company now operates as Genesis Molecular AI. Its platform, GEMS, combines foundation models with physics-based methods for molecular design. In October 2025 it released Pearl, a foundation model for predicting protein-ligand structure, and later published follow-up results on benchmark performance and model distillation. In December 2025 it appointed Sergey Edunov as Senior Vice President of Foundation Models. The company’s partnership with Incyte grew substantially in May 2026: Incyte agreed to pay $80 million upfront in cash, buy $40 million of Genesis equity and add at least five new targets. Milestone payments could reach up to $232 million per program. Feinberg called the deal “an important moment in the evolution of AI in this vertical.”

Genesis is headquartered in the San Francisco Bay Area and also has offices in San Diego and New York.

Education

Stanford University

PhD, Computational Biophysics

Yale University

BS, Applied Physics